I. COMMENCED TRADING IN MARCH | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
INITIAL OFFERINGS | ||||||||
There were no initial public offerings that commenced in March. | ||||||||
Total: $0M Number of IPOs in March: 0 Average value of March IPOs: $0M Number of IPOs in 20 11: 6 Total raised in IPOs in 20 11: $308.5M Average value of IPOs in 20 11: $51.42M | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
FOLLOW-ON OFFERINGS | ||||||||
Affymax Inc. (Palo Alto, Calif.; AFFY)1 |
4/22 2010 |
3/18 |
8.47S |
$5.90 |
33.9 |
Lazard Capital Markets |
$49.97 |
$200.01 |
Catalyst Pharmaceuticals Partners Inc. (Coral Gables, Fla.; CPRX) |
12/15 |
3/8 |
2.3S |
$1.12 |
21 .65 |
Roth Capital Partners |
$2.53 |
$24.25 |
Exelixis Inc. (South San Francisco; EXEL)2 |
5/8 |
3/10 |
17.25S |
$11 |
126.6 |
Goldman, Sachs & Co. |
$189.75 |
$1.39B |
Gilead Sciences Inc. (Foster City, Calif.; GILD)3 |
3/23 |
3/24 |
Notes |
N/A |
N/A |
BofA Merrill Lynch |
$1B |
N/A |
MediciNova Inc. (San Diego; MNOV)4 |
12/16 2009 |
3/24 |
2.75U |
$3 |
15.18 |
Ladenburg, Thalmann & Co. |
$8.25 |
$45.54 |
OPKO Health Inc. (Miami; OPKO)5 |
2/11 |
3/10 |
29.4S |
$3.75 |
284.8 |
Jefferies |
$110.25 |
$1.07B |
Protalix BioTherapeutics Inc. (Carmiel, Israel; NYSE:PLX) |
1/13 |
3/18 |
4S |
$5.50 |
85.25 |
Citibank |
$22 |
$468.88 |
RXi Pharmaceuticals Corp. (Worcester, Mass.; RXII) |
5/21 |
3/1 |
6U |
$1.35 |
24.4 |
Lazard Capital Markets |
$8.1 |
$32.94 |
Stem Cell Therapeutics Corp. (Calgary, Alberta; TSX:SSS) |
3/1 |
3/22 |
18.18U |
C$0.11 |
N/A |
Euro Pacific Canada Inc. |
C$2 ($2.03) |
N/A |
Threshold Pharmaceuticals Inc. (Redwood City, Calif.; THLD)6 |
10/15 2010 |
3/11 |
14.3U |
$2.10 |
48.8 |
Cowen & Co. |
$30 |
$102.48 |
Total: $1,422.88M Number of follow-on offerings in March: 10 Average value of March follow-ons: $142.3M Number of follow-on offerings in 20 11: 30 Total raised in follow-ons in 20 11: $2,848.695M Average value of follow-ons in 20 11: $94.96M | ||||||||
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. 1 Affymax's overallotment option: 1.27M shares. 2 Includes Exelixis' overallotment option: 2.25M shares. 3 Gilead Science's offering is of senior unsecured notes with an annual interest rate of 4.5 percent. They will mature on April 1, 2021. 4 MediciNova's overallotment option: 412,500 shares. 5 Includes OPKO's overallotment option: 2.4M shares. 6 Threshold's units consist of 14.3M shares of common stock and warrants to purchase an additional 5.7M shares. |
II. FILED AND PENDING | ||||||
Company (Symbol)# |
Date Filed |
Shares/ Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters (M)@ |
Gross (US$M) |
INITIAL OFFERINGS | ||||||
Aldagen Inc. (ALDH) |
10/29/09 |
Units |
N/A |
N/A |
Boenning & Scattergood |
$46 |
Ambit Biosciences Corp. (AMBT) |
11/5/10 |
N/A |
N/A |
N/A |
J.P. Morgan |
$86.25 |
BioLineRx Ltd. (BLRX) |
9/24/10 |
N/A |
N/A |
N/A |
JMP Securities Oppenheimer & Co. |
$40.25 |
Clarus Therapeutics Inc. (Northbrook, Ill.; CLRS) |
11/19/10 (Postponed 2/16) |
5S |
$11-$13 |
18.1 |
Piper Jaffray |
$60 |
Cutanea Life Sciences Inc. (CTNA)1 |
11/5/10 |
2.3S |
$6.50 |
3.9 |
Brean Murray, Carret & Co. |
$14.95 |
Horizon Pharma Inc. (HZNP) |
8/3/10 |
N/A |
N/A |
N/A |
Jefferies & Co. |
$86.25 |
Insys Therapeutics Inc. (Phoenix; INRX) |
3/30/11 |
N/A |
N/A |
N/A |
Wells Fargo Securities |
$55 |
Med BioGene Inc.2 (Canada; MGBI) |
12/28/09 |
N/A |
N/A |
N/A |
Rodman & Renshaw LLC |
$24 |
NewLink Genetics Corp. (NLNK) |
12/21/10 |
N/A |
N/A |
N/A |
Wells Fargo |
$86.25 |
Prometheus RxDx Corp. (RXDX) |
12/19/07 |
N/A |
N/A |
N/A |
Goldman Sachs & Co. |
$151.3 |
Quark Pharmaceuticals Inc. (TASE) |
9/28/10 |
N/A |
N/A |
N/A |
N/A |
$20 |
Sagent Pharmaceuticals Inc. (SGNT) |
12/7/10 |
N/A |
N/A |
N/A |
Morgan Stanley |
$100 |
Supernus Pharmaceuticals Inc. (SUPN) |
12/23/10 |
N/A |
N/A |
N/A |
Citibank |
$100 |
Tranzyme Pharma Inc. (TZYM)3 |
11/19/10 |
13.5S |
$4 |
23.7 |
Citigroup Global Markets |
$54 |
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. General shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. 1 Cutanea's overallotment option: 345,000 shares. 2 Med BioGene is already listed on the Canadian Venture Exchange, ticker symbol "MBI." 3 Tranzyme priced its IPO on April 1 to offer 13.5M shares at $4 each. The completed IPO will be listed next month in the April financings chart. Overallotment option: 1.48M shares. |